Intravenous minocycline in multidrug-resistant infections: a profile of its use in the USA with a focus on Acinetobacter infections
2018-04-11T00:26:58Z (GMT) by
Compliance with ethical standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: K.A. Lyseng-Williamson, S.L. Greig SL, and L.J. Scott are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
Additional information about this Adis Drug Review can be found here.
Intravenous (IV) minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of many bacteria (e.g. Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp.). Minocycline shows antibacterial activity against A. baumannii clinical isolates worldwide, and exhibits synergistic bactericidal activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) A. baumanniiisolates when combined with other antibacterial agents. In retrospective studies, IV minocycline provided high rates of clinical success or improvement, and was generally well tolerated among patients with MDR or carbapenem-resistant A. baumannii infections. Access to the full article can be found here.
© Springer International Publishing AG, part of Springer Nature 2017